340 related articles for article (PubMed ID: 9345342)
1. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
2. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
[TBL] [Abstract][Full Text] [Related]
7. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
10. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
14. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
Wrigley E; Weaver A; Jayson G; Ranson M; Renninson J; Prendiville J; Dobson M; Collins CD; Swindell R; Buckley CH; Radford JA; Crowther D
Ann Oncol; 1996 Sep; 7(7):705-11. PubMed ID: 8905028
[TBL] [Abstract][Full Text] [Related]
15. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
17. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
19. Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung.
Shaw EG; Frytak S; Eagan RT; Richardson RL; Creagan ET; Jett JR; Foote RL; Su JQ; Schaid DJ; Lee RE
Am J Clin Oncol; 1996 Apr; 19(2):154-8. PubMed ID: 8610640
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group.
Tropé C; Andersson H; Björkholm E; Frankendal B; Himmelman A; Högberg T; Horvath G; Petterson B; Persson H; Ryberg M; Simonsen E; Sorbe B; Stendahl U; Westholm B
Acta Oncol; 1996; 35 Suppl 8():109-18. PubMed ID: 9073056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
